Hubungan Kadar Serum Cancer Antigen-125 dengan Stadium Kanker Ovarium Tipe Epitel

Correlation between Serum Levels of Cancer Antigen-125 and Stages of Epithelial Type Ovarian Cancer

Penulis

  • Della Ayu Lestari Program Studi Kedokteran, Fakultas Kedokteran, Universitas Mulawarman, Samarinda, Indonesia Penulis
  • Eva Rachmi Program Studi Kedokteran, Fakultas Kedokteran, Universitas Mulawarman, Samarinda, Indonesia Penulis https://orcid.org/0000-0003-2945-5001
  • Andika Adi Saputra Achmad Program Studi Profesi Dokter, Fakultas Kedokteran, Universitas Mulawarman, Samarinda, Indonesia Penulis

Kata Kunci:

Kadar Serum CA-125, Kanker Ovarium Tipe Epitel, Stadium

Abstrak

Kanker ovarium memiliki prognosis terburuk dari seluruh keganasan ginekologi pada wanita. Kesintasan lima tahun kanker ovarium hanya 30%–50% di Indonesia. Tipe histologis paling umum pada insidensi kanker ovarium adalah kanker ovarium tipe epitel (90%). Kanker ovarium masih menjadi salah satu kanker ginekologi paling mematikan karena belum ada teknik yang efektif untuk memprediksi stadium kanker ovarium. Akurasi CA-125 sebagai salah satu penanda tumor dalam menentukan stadium kanker ovarium masih menjadi perdebatan. Penelitian ini menganalisis hubungan antara kadar serum CA-125 dengan stadium kanker ovarium tipe epitel di RSUD Abdoel Wahab Sjahranie Samarinda, yang dilakukan pada bulan Agustus hingga Desember 2023. Penelitian ini berupa observasional analitik dengan pendekatan cross-sectional. Teknik pengambilan sampel melalui purposive sampling, dengan data sekunder berupa rekam medis. Sampel berjumlah 30 pasien. Analisis bivariat dilakukan dengan uji one way ANOVA. Hubungan antara kadar serum CA-125 dengan stadium kanker ovarium tipe epitel secara keseluruhan adalah tidak bermakna (p = 0,052). Uji lanjut didapatkan perbedaan yang bermakna antara kadar serum CA-125 dengan stadium kanker ovarium tipe epitel, khususnya pada stadium I dan stadium III (p = 0,027).

Referensi

Zhang Y, Luo G, Li M, Guo P, Xiao Y, Ji H, et al. Global patterns and trends in ovarian cancer incidence: Age, period and birth cohort analysis. BMC Cancer. 2019;19(1):1–14.

Globocan. The Global Cancer Observatory: All Cancer [Internet]. International Agency for Research on Cancer. 2020 [cited 2023 Aug 30]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/25-Ovary-fact-sheet.pdf

Harsono AB. Kanker Ovarium?: “The Silent Killer.” Indones J Obstet Gynecol Sci. 2020;3(1):1–6.

Reza H, Andriani NA, Suwantari SA. Karakteristik Klinis Dan Histopatologi Kanker Ovarium Epitelial Yang Menjalani Operasi Di RSUP Dr. Sardjito. 2022;13(4):397–402.

Tanha K, Mottaghi A, Nojomi M, Moradi M, Rajabzadeh R, Lotfi S, et al. Investigation on factors associated with ovarian cancer: an umbrella review of systematic review and meta-analyses. J Ovarian Res [Internet]. 2021;14(1):1–17. Available from: https://doi.org/10.1186/s13048-021-00911-z

Kossaï M, Leary A, Scoazec JY, Genestie C. Ovarian Cancer: A Heterogeneous Disease. Pathobiology. 2018;85(1–2):41–9.

Globocan. The Global Cancer Observatory: Indonesia [Internet]. International Agency for Research on Cancer. 2020 [cited 2023 Aug 30]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf

Ruiz MP, Morales-Ramirez PB, Dziadek OL, Algren SD. Epithelial ovarian cancer and type of peritoneal insult: a case–control study. Eur J Obstet Gynecol Reprod Biol [Internet]. 2016;205:170–3. Available from: http://dx.doi.org/10.1016/j.ejogrb.2016.07.494

Gaitskell K, Green J, Pirie K, Barnes I, Hermon C, Reeves GK, et al. Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study. Int J Cancer. 2018;142(2):281–9.

Lahmuddin T, Maulani H, Musa Z, Saleh I. Korelasi Antara Overekspresi p53 Dengan Derajat Histopatologi Dan Stadium Klinis Karsinoma Ovarium. 2015;2(3):267–75.

Assidi M. High N-Cadherin Protein Expression in Ovarian Cancer Predicts Poor Survival and Triggers Cell Invasion. Front Oncol. 2022;12(April):1–10.

Menon U, Karpinskyj C, Gentry-Maharaj A. Ovarian Cancer Prevention and Screening. Obstet Gynecol. 2018;131(5):909–27.

Ali AT. Towards prevention of ovarian cancer. Curr Cancer Drug Targets [Internet]. 2018;(18):522–37. Available from: https://www.ingentaconnect.com/content/ben/ccdt/2018/00000018/00000006/art00004

Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. Ca125 and ovarian cancer: A comprehensive review. Cancers (Basel). 2020;12(12):1–29.

Gea IT, Loho MF, Wagey FW. Gambaran jenis kanker ovarium di RSUP Prof . Dr . R . D . Kandou Manado. E-Clinic. 2016;4:2–6.

Batool A, Rathore Z, Jahangir F, Javeed S, Nasir S, Chughtai AS. Histopathological Spectrum of Ovarian Neoplasms: A Single-Center Study. Cureus. 2022;14(November 2020).

Doroudi M, Kramer BS, Pinsky PF. The bimanual ovarian palpation examination in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: Performance and complications. J Med Screen. 2017 Dec;24(4):220–2.

Openshaw MR, McVeigh TP. Non-invasive Technology Advances in Cancer—A Review of the Advances in the Liquid Biopsy for Endometrial and Ovarian Cancers. Front Digit Heal. 2020;2(December):1–15.

Suastari NMP. Pemeriksaan Radiologi untuk Deteksi Kanker Payudara. Cermin Dunia Kedokt [Internet]. 2018;45(4):226–9. Available from: http://www.cdkjournal.com/index.php/CDK/article/view/837/593%0Ahttp://www.cdkjournal.com/index.php/CDK/article/view/837

Bast RC, Lu Z, Han CY, Lu KH, Anderson KS, Drescher CW, et al. Biomarkers and strategies for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2020;29(12):2504–12.

Nash Z, Menon U. Ovarian cancer screening: Current status and future directions. Best Pract Res Clin Obstet Gynaecol [Internet]. 2020;65:32–45. Available from: https://doi.org/10.1016/j.bpobgyn.2020.02.010

22. Sabaruddin H, Ferry A. Korelasi Tumor Marker Cancer Antigen(CA-125) terhadap kadar Hemoglobin, Leukosit, dan Platelet Limfosit Ratio pada Pasien Kanker Ovarium di RSUD ULIN Banjarmasin. J Ilm Kedokt Wijaya Kusuma. 2018;7(1):93–106.

Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynecol Obstet. 2021;155(S1):61–85.

Merritt MA, De Pari M, Vitonis AF, Titus LJ, Cramer DW, Terry KL. Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod. 2013;28(5):1406–17.

Elias KM, Guo J, Bast RC. Early Detection of Ovarian Cancer. Hematol Oncol Clin North Am. 2018;32(6):903–14.

Colombo N, Sessa C, Du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672–705.

Mukama T, Fortner RT, Katzke V, Hynes LC, Petrera A, Hauck SM, et al. Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer. Br J Cancer. 2022;126(9):1301–9.

Wijaya R, Murti K, Hafy Z. Hubungan Kadar CA-125 dengan Subtipe Epitel Tumor Ganas Ovarium pada Penderita yang Dirawat di RSUP Dr. Mohammad Hoesin Palembang Tahun 2013-2016. Maj Kedokt Sriwij [Internet]. 2017;49(4):197–204. Available from: https://ejournal.unsri.ac.id/index.php/mks/article/view/8526

Aditiyono AA, Harsono AB, Susanto H. Ca 125 Dan Risk of Malignancy Index (RMI)2 Sebagai Prediktor Keganasan Tumor Ovarium Tipe Epitel. Mandala Heal. 2018;11(1):18.

Bonifácio VDB. Ovarian Cancer Biomarkers: Moving Forward in Early Detection. Adv Exp Med Biol. 2020;1219(18):355–63.

Pradjatmo H. Impact of preoperative serum levels of CA 125 on epithelial ovarian cancer survival. Asian Pacific J Cancer Prev. 2016;17(4):1881–6.

Morales-Vásquez F, Pedernera E, Reynaga-Obregón J, López-Basave HN, Gómora MJ, Carlón E, et al. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma. J Ovarian Res [Internet]. 2016;9(1):1–6. Available from: http://dx.doi.org/10.1186/s13048-016-0247-6

Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12(1):1–9.

Xu M, Wang B, Shi Y. Borderline ovarian tumor in the pediatric and adolescent population: a clinopathologic analysis of fourteen cases. Int J Clin Exp Pathol [Internet]. 2020;13(5):1053–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32509078%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7270684

Kristjansdottir B, Levan K, Partheen K, Sundfeldt K. Diagnostic performance of the biomarkers HE4 and CA125 in type i and type II epithelial ovarian cancer. Gynecol Oncol [Internet]. 2013;131(1):52–8. Available from: http://dx.doi.org/10.1016/j.ygyno.2013.07.094

Osman N, O’Leary N, Higgins MJ, Barrett N, Wallis F, Gupta KHRK. Correlation of serum CA125 levels with stage, grade and survival of patients with epithelial ovarian cancer. J Clin Oncol [Internet]. 2008;25(18):245–7. Available from: https://ascopubs.org/doi/abs/10.1200/jco.2007.25.18_suppl.16066?role=tab

Prajatmo H, Siswishanto R, Prawitasari S. Hubungan Kadar CA-125 Praoperatif terhadap Prognosis Survival Penderita Kanker Ovarium Epitelial di RSUP Dr. Sardjito. J Kesehat Reproduksi. 2018;5(1):15–23.

Pemaron IBR. Perbedaan Kadar Cancer Antigen-125 dan Human Epididimis-4 Pada Kanker Ovarium Tipe Epitelial Stadium I, Stadium II, dan Stadium III. Universitas Udayana; 2016.

Gandhi T, Zubair M, Bhatt H. Cancer Antigen 125 [Internet]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023 [cited 2023 Sep 5]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562245/

Hu X, Zhang J, Cao Y. Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study. BMC Cancer [Internet]. 2022;22(1):1–14. Available from: https://doi.org/10.1186/s12885-022-09637-7

Kim JH, Park BR, Yang WJ. Dilution effect of serum CA125 and CA19-9 over a cutoff value, according to obesity. Int J Biol Markers. 2015;30(1):e122–6.

Darwizar BD, Nyarumenteng G, Winarno A, Hasan R, Bandung S. CA-125 Prediktor Sitoreduksi pada Pasien Kanker Ovarium Tipe Epitel. Indones J Obstet Gynecol Sci. 2023;6:255–62.

Kumar V, Abbas AK, Aster JC. Robbins & Cotran Pathologic Basis of Disease. 10th ed. Turner JR, editor. Philadelphia: Elsevier; 2021. 1377 p.

Redondo A, Guerra E, Manso L, Martin-Lorente C, Martinez-Garcia J, Perez-Fidalgo JA, et al. SEOM clinical guideline in ovarian cancer (2020). Clin Transl Oncol [Internet]. 2021;23(5):961–8. Available from: https://doi.org/10.1007/s12094-020-02545-x

Wang Q, Feng X, Liu X, Zhu S. Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis. Front Oncol. 2022;12(April):1–10.

Nazmeen A, Maiti S, Mandal K, Roy SK, Ghosh TK, Sinha NK, et al. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease. Bentham Sci [Internet]. 2017;13(8):796–804. Available from: https://www.eurekaselect.com/article/82989

Diterbitkan

2024-11-14

Terbitan

Vol 6 No 3 (2024): J. Sains Kes.

Bagian

Articles

Cara Mengutip

Hubungan Kadar Serum Cancer Antigen-125 dengan Stadium Kanker Ovarium Tipe Epitel: Correlation between Serum Levels of Cancer Antigen-125 and Stages of Epithelial Type Ovarian Cancer. (2024). Jurnal Sains Dan Kesehatan, 6(3), 378-384. https://jsk.ff.unmul.ac.id/index.php/JSK/article/view/21